Fernanda G De Felice

List of Publications by Year
in descending order

101	12,473	28736 57	37326 100
papers	citations	h-index	g-index

106	106	106	16208
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Characterization of cerebrospinal fluid biomarkers associated with neurodegenerative diseases in healthy cynomolgus and rhesus macaque monkeys. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12289.	1.8	1
2	Impaired insulin signalling and allostatic load in Alzheimer disease. Nature Reviews Neuroscience, 2022, 23, 215-230.	4.9	72
3	Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology, 2022, 209, 109023.	2.0	38
4	Blood-Based Biomarkers for COVID-19-Associated Neurological Outcomes. Biological Psychiatry, 2022, 91, S28.	0.7	0
5	Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimerâ€™s disease. Science Signaling, 2021, 14, .	1.6	75
6	Interleukin-1Î² mediates alterations in mitochondrial fusion/fission proteins and memory impairment induced by amyloid-Î² oligomers. Journal of Neuroinflammation, 2021, 18, 54.	3.1	40
7	Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimerâ€™s disease. Translational Psychiatry, 2021, 11, 251.	2.4	112
8	Combination of human tau and islet amyloid polypeptide exacerbates metabolic dysfunction in transgenic mice. Journal of Pathology, 2021, 254, 244-253.	2.1	9
9	Cerebrospinal Fluid Neurotransmitters, Cytokines, and Chemokines in Alzheimerâ€™s and Lewy Body Diseases. Journal of Alzheimer's Disease, 2021, 82, 1067-1074.	1.2	13
10	The crosstalk between brain and periphery: Implications for brain health and disease. Neuropharmacology, 2021, 197, 108728.	2.0	17
11	The impact of SARSâ€CoVâ€2 in dementia across Latin America: A call for an urgent regional plan and coordinated response. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12092.	1.8	21
12	The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12069.	1.2	6
13	Protective actions of exerciseâ€related FNDC5/Irisin in memory and Alzheimerâ€™s disease. Journal of Neurochemistry, 2020, 155, 602-611.	2.1	45
14	Behavioral Abnormalities in Knockout and Humanized Tau Mice. Frontiers in Endocrinology, 2020, 11, 124.	1.5	29
15	Cerebrospinal fluid irisin correlates with amyloidâ€Î², BDNF, and cognition in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12034.	1.2	32
16	Palmitate Is Increased in the Cerebrospinal Fluid of Humans with Obesity and Induces Memory Impairment in Mice via Pro-inflammatory TNF-Î±. Cell Reports, 2020, 30, 2180-2194.e8.	2.9	80
17	Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease. Neuropharmacology, 2020, 171, 108115.	2.0	27
18	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System. Trends in Neurosciences, 2020, 43, 355-357.	4.2	193

#	Article	IF	Citations
19	Association between diabetes and mood disorders and the potential use of anti-hyperglycemic agents as antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109720.	2.5	35
20	Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice. Nature Communications, 2019, 10, 3890.	5.8	135
21	Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes. Frontiers in Psychiatry, 2019, 10, 57.	1.3	93
22	Neonatal infection leads to increased susceptibility to AÎ² oligomer-induced brain inflammation, synapse loss and cognitive impairment in mice. Cell Death and Disease, 2019, 10, 323.	2.7	23
23	Potentials and Pitfalls of Cross-Translational Models of Cognitive Impairment. Frontiers in Behavioral Neuroscience, 2019, 13, 48.	1.0	29
24	Understanding the link between insulin resistance and Alzheimerâ€™s disease: Insights from animal models. Experimental Neurology, 2019, 316, 1-11.	2.0	28
25	The Link Between Tau and Insulin Signaling: Implications for Alzheimerâ€™s Disease and Other Tauopathies. Frontiers in Cellular Neuroscience, 2019, 13, 17.	1.8	68
26	Extracellular vesicles derived from human Whartonâ€™s jelly mesenchymal stem cells protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-Î² oligomers. Stem Cell Research and Therapy, 2019, 10, 332.	2.4	86
27	Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimerâ€™s models. Nature Medicine, 2019, 25, 165-175.	15.2	511
28	Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimerâ€™s and Parkinsonâ€™s Diseases. CNS Drugs, 2019, 33, 209-223.	2.7	49
29	Long-term consequences of the absence of leptin signaling in early life. ELife, 2019, 8, .	2.8	31
30	Brain STAT5 signaling modulates learning and memory formation. Brain Structure and Function, 2018, 223, 2229-2241.	1.2	29
31	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a nonâ€human primate model of Alzheimer's disease. Journal of Pathology, 2018, 245, 85-100.	2.1	180
32	Mesenchymal stem cells and cell-derived extracellular vesicles protect hippocampal neurons from oxidative stress and synapse damage induced by amyloid-Î² oligomers. Journal of Biological Chemistry, 2018, 293, 1957-1975.	1.6	146
33	Metabolic Dysfunction in Alzheimerâ€™s Disease: From Basic Neurobiology to Clinical Approaches. Journal of Alzheimer's Disease, 2018, 64, S405-S426.	1.2	66
34	Brain-Defective Insulin Signaling Is Associated to Late Cognitive Impairment in Post-Septic Mice. Molecular Neurobiology, 2018, 55, 435-444.	1.9	26
35	Impaired peripheral glucose homeostasis and Alzheimer's disease. Neuropharmacology, 2018, 136, 172-181.	2.0	61
36	Connecting Alzheimer's disease to diabetes: Underlying mechanisms and potential therapeutic targets. Neuropharmacology, 2018, 136, 160-171.	2.0	99

#	Article	IF	Citations
37	Expression of dopamine signaling genes in the post-mortem brain of individuals with mental illnesses is moderated by body mass index and mediated by insulin signaling genes. Journal of Psychiatric Research, 2018, 107, 128-135.	1.5	17
38	Insulin Resistance in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 830.	1.4	147
39	Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones?. Neuropharmacology, 2018, 136, 159.	2.0	3
40	Free-floating adult human brain-derived slice cultures as a model to study the neuronal impact of Alzheimerâ€™s disease-associated AÎ² oligomers. Journal of Neuroscience Methods, 2018, 307, 203-209.	1.3	27
41	Tau ablation in mice leads to pancreatic Î² cell dysfunction and glucose intolerance. FASEB Journal, 2018, 32, 3166-3173.	0.2	43
42	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. Frontiers in Neuroscience, 2018, 12, 37.	1.4	132
43	Acute and chronic neurological consequences of early-life Zika virus infection in mice. Science Translational Medicine, 2018, 10, .	5.8	109
44	The Role of Leptin and Adiponectin in Obesity-Associated Cognitive Decline and Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2018, 12, 1027.	1.4	136
45	Getting a â€œGRiPâ€•on Hypothalamic Endoplasmic Reticulum Stress to Combat Obesity. Diabetes, 2017, 66, 17-19.	0.3	6
46	Interaction of amyloid-Î² (AÎ²) oligomers with neurexin 2Î± and neuroligin 1 mediates synapse damage and memory loss in mice. Journal of Biological Chemistry, 2017, 292, 7327-7337.	1.6	67
47	Chronic sleep restriction promotes brain inflammation and synapse loss, and potentiates memory impairment induced by amyloid-Î² oligomers in mice. Brain, Behavior, and Immunity, 2017, 64, 140-151.	2.0	89
48	Astrocyte Transforming Growth Factor Beta 1 Protects Synapses against AÎ² Oligomers in Alzheimer's Disease Model. Journal of Neuroscience, 2017, 37, 6797-6809.	1.7	127
49	Amyloid-Î² oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. Journal of Biological Chemistry, 2017, 292, 7395-7406.	1.6	51
50	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound AÎ² oligomers. Molecular Biology of the Cell, 2017, 28, 2623-2636.	0.9	88
51	Brain infusion of Î±-synuclein oligomers induces motor and non-motor Parkinsonâ€™s disease-like symptoms in mice. Behavioural Brain Research, 2017, 333, 150-160.	1.2	27
52	Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimerâ€™s Therapy?. Frontiers in Aging Neuroscience, 2017, 9, 7.	1.7	80
53	Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer's Amyloid-Î² Oligomers in Mice. Journal of Neuroscience, 2016, 36, 12106-12116.	1.7	116
54	Opportunities and challenges in developing relevant animal models for Alzheimerâ€™s disease. Ageing Research Reviews, 2016, 26, 112-114.	5.0	40

#	Article	IF	Citations
55	Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Aging Neuroscience, 2015, 7, 94.	1.7	91
56	A Key Role of Insulin Receptors in Memory. Diabetes, 2015, 64, 3653-3655.	0.3	50
57	Alzheimerâ€“associated AÎ² oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Molecular Medicine, 2015, 7, 190-210.	3.3	176
58	Soluble amyloid-ÃŽÂ² oligomers as synaptotoxins leading to cognitive impairment in AlzheimerÃ¢â‚¬â„¢s disease. Frontiers in Cellular Neuroscience, 2015, 9, 191.	1.8	284
59	Neuronal stress signaling and eIF2Î± phosphorylation as molecular links between Alzheimer's disease and diabetes. Progress in Neurobiology, 2015, 129, 37-57.	2.8	65
60	Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, S76-83.	0.4	271
61	Alzheimer's Disease-Like Pathology Induced by Amyloid-Î² Oligomers in Nonhuman Primates. Journal of Neuroscience, 2014, 34, 13629-13643.	1.7	189
62	Astrocyte transforming growth factor beta 1 promotes inhibitory synapse formation via CaM kinase II signaling. Glia, 2014, 62, 1917-1931.	2.5	89
63	Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease. Diabetes, 2014, 63, 2262-2272.	0.3	462
64	How does brain insulin resistance develop in Alzheimer's disease?. Alzheimer's and Dementia, 2014, 10, S26-32.	0.4	261
65	Intranasal Insulin as a Treatment for Alzheimerâ€™s Disease: A Review of Basic Research and Clinical Evidence. CNS Drugs, 2013, 27, 505-514.	2.7	402
66	Connecting Type 2 diabetes to Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2013, 13, 1297-1299.	1.4	16
67	TNF-Î± Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimerâ€™s Î²-Amyloid Oligomers in Mice and Monkeys. Cell Metabolism, 2013, 18, 831-843.	7.2	340
68	Memantine Rescues Transient Cognitive Impairment Caused by High-Molecular-Weight AÂ Oligomers But Not the Persistent Impairment Induced by Low-Molecular-Weight Oligomers. Journal of Neuroscience, 2013, 33, 9626-9634.	1.7	160
69	Alzheimerâ€™s disease and insulin resistance: translating basic science into clinical applications. Journal of Clinical Investigation, 2013, 123, 531-539.	3.9	285
70	Amyloid-Î² Oligomers Induce Differential Gene Expression in Adult Human Brain Slices. Journal of Biological Chemistry, 2012, 287, 7436-7445.	1.6	80
71	An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimerâ€™s diseaseâ€“associated AÎ² oligomers. Journal of Clinical Investigation, 2012, 122, 1339-1353.	3.9	697
72	Amyloid-beta oligomers increase the localization of prion protein at the cell surface. Journal of Neurochemistry, 2011, 117, 538-553.	2.1	60

#	Article	IF	Citations
73	Activation of D1/D5 Dopamine Receptors Protects Neurons from Synapse Dysfunction Induced by Amyloid-Î² Oligomers. Journal of Biological Chemistry, 2011, 286, 3270-3276.	1.6	77
74	Expression Profile of Rat Hippocampal Neurons Treated with the Neuroprotective Compound 2,4-Dinitrophenol: Up-Regulation of cAMP Signaling Genes. Neurotoxicity Research, 2010, 18, 112-123.	1.3	17
75	Nâ€Methylâ€<scp>d</scp>â€aspartate receptors are required for synaptic targeting of Alzheimerâ€™s toxic amyloidâ€Î² peptide oligomers. Journal of Neurochemistry, 2010, 115, 1520-1529.	2.1	141
76	Amyloid-Î² Triggers the Release of Neuronal Hexokinase 1 from Mitochondria. PLoS ONE, 2010, 5, e15230.	1.1	86
77	Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of AÎ² oligomers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1971-1976.	3.3	592
78	Alzheimer's-associated AÎ² oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicology and Applied Pharmacology, 2009, 240, 189-197.	1.3	127
79	Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB Journal, 2008, 22, 246-260.	0.2	514
80	Alzheimer's disease-type neuronal tau hyperphosphorylation induced by AÎ² oligomers. Neurobiology of Aging, 2008, 29, 1334-1347.	1.5	386
81	Cyclic AMP Enhancers and AÎ² Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease. Current Alzheimer Research, 2007, 4, 263-271.	0.7	44
82	AÎ² Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine. Journal of Biological Chemistry, 2007, 282, 11590-11601.	1.6	769
83	Monoclonal antibodies that target pathological assemblies of AÎ². Journal of Neurochemistry, 2007, 100, 23-35.	2.1	308
84	Soluble oligomers from a nonâ€disease related protein mimic AÎ²â€induced tau hyperphosphorylation and neurodegeneration. Journal of Neurochemistry, 2007, 103, 736-748.	2.1	78
85	Soluble protein oligomers as emerging toxins in alzheimer's and other amyloid diseases. IUBMB Life, 2007, 59, 332-345.	1.5	289
86	Molecules that Disrupt Memory Circuits in Alzheimerâ€™s Disease: The Attack on Synapses by AÎ² Oligomers (ADDLs). Research and Perspectives in Neurosciences, 2007, , 155-179.	0.4	13
87	Novel neuroprotective, neuritogenic and anti-amyloidogenic properties of 2,4-dinitrophenol: The gentle face of Janus. IUBMB Life, 2006, 58, 185-191.	1.5	44
88	Metastable, Partially Folded States in the Productive Folding and in the Misfolding and Amyloid Aggregation of Proteins. Cell Biochemistry and Biophysics, 2006, 44, 539-548.	0.9	24
89	Small Molecule Inhibitors of Lysozyme Amyloid Aggregation. Cell Biochemistry and Biophysics, 2006, 44, 549-553.	0.9	54
90	Mitochondrial Creatine Kinase Activity Prevents Reactive Oxygen Species Generation. Journal of Biological Chemistry, 2006, 281, 37361-37371.	1.6	167

#	Article	IF	Citations
91	Formation of Soluble Oligomers and Amyloid Fibrils with Physical Properties of the Scrapie Isoform of the Prion Protein from the C-terminal Domain of Recombinant Murine Prion Protein mPrP-(121â€“231). Journal of Biological Chemistry, 2006, 281, 26121-26128.	1.6	30
92	Neuritogenesis and neuronal differentiation promoted by 2,4â€dinitrophenol, a novel antiâ€amyloidogenic compound. FASEB Journal, 2005, 19, 1627-1636.	0.2	42
93	Activation of GABAA receptors by taurine and muscimol blocks the neurotoxicity of Î²-amyloid in rat hippocampal and cortical neurons. Neuropharmacology, 2005, 49, 1140-1148.	2.0	70
94	Targeting the neurotoxic species in Alzheimer's disease: inhibitors of AÎ² oligomerization. FASEB Journal, 2004, 18, 1366-1372.	0.2	190
95	Mitochondrial Bound Hexokinase Activity as a Preventive Antioxidant Defense. Journal of Biological Chemistry, 2004, 279, 39846-39855.	1.6	245
96	Formation of amyloid aggregates from human lysozyme and its diseaseâ€associated variants using hydrostatic pressure. FASEB Journal, 2004, 18, 1099-1101.	0.2	81
97	Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cellular and Molecular Neurobiology, 2002, 22, 545-563.	1.7	65
98	Protein dynamics, folding and misfolding: from basic physical chemistry to human conformational diseases. FEBS Letters, 2001, 498, 129-134.	1.3	57
99	Inhibition of Alzheimer's disease Î²â€amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. FASEB Journal, 2001, 15, 1297-1299.	0.2	117
100	Selective Neoglycosylation Increases the Structural Stability of Vicilin, the 7S Storage Globulin from Pea Seeds. Archives of Biochemistry and Biophysics, 2000, 382, 203-210.	1.4	46
101	Subunit dissociation and inactivation of pyruvate kinase by hydrostatic pressure. Oxidation of sulfhydryl groups and ligand effects on enzyme stability. FEBS Journal, 1999, 266, 163-169.	0.2	12